Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023473 (
chronic myeloid leukemia
)
18,916
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The expression of the
suppressor of cytokine signalling-1
(
SOCS1
) protein is induced in response to stimulation by several cytokines. The induced
SOCS1
inhibits the signalling pathway through the association with a variety of tyrosine kinase proteins. In this study, the mutation analyses, CpG island methylation status, and the expression of the
SOCS1
gene in 112
chronic myeloid leukaemia
(
CML
) samples, five leukaemia cell lines, and 30 normal controls were analysed. No genetic mutations of
SOCS1
gene were noted in the
CML
samples. The
SOCS1
gene was hypermethylated in 67% and 46% of the blastic and chronic phase CML samples respectively (P < 0.0001). However, there was no methylation of the
SOCS1
gene in normal controls or
CML
in molecular remission. The methylation status of the
SOCS1
gene is consistent with the results of the real-time quantitative reverse transcription polymerase chain reaction and immunocytochemistry staining. Our results demonstrate that the
SOCS1
gene silencing is caused by the methylation of CpG islands in
CML
and is reversed to an unmethylated status in molecular remission. As
SOCS1
has universal activity to negatively regulate several cytokine signalling pathways, the loss of the negative regulation of cytokine signalling by the
SOCS1
may play a role in the pathogenesis of CML progression.
...
PMID:Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia. 1461 69